Pedro Giro MD , Mallory Filipp PhD , Michael J. Zhang MD, PhD , Ethan D. Moser MPH , Edward B. Thorp PhD , Prarthana J. Dalal MD, PhD , Ravi V. Shah MD , Patrick T. Ellinor MD, PhD , Jonathan W. Cunningham MD , Sean J. Jurgens MD, MSc , Arjun Sinha MD, MSc , Laura Rasmussen-Torvik PhD, MPH , Jorge Kizer MD, MSc , Kent D. Taylor PhD , Philip Greenland MD , Bruce M. Psaty MD, PhD , Russell P. Tracy PhD , Lin Yee Chen MD, MS , Amil M. Shah MD , Bing Yu PhD , Ravi B. Patel MD, MSc
{"title":"Proteomic Profile of the ICAM1 p.K56M HFpEF Risk Variant","authors":"Pedro Giro MD , Mallory Filipp PhD , Michael J. Zhang MD, PhD , Ethan D. Moser MPH , Edward B. Thorp PhD , Prarthana J. Dalal MD, PhD , Ravi V. Shah MD , Patrick T. Ellinor MD, PhD , Jonathan W. Cunningham MD , Sean J. Jurgens MD, MSc , Arjun Sinha MD, MSc , Laura Rasmussen-Torvik PhD, MPH , Jorge Kizer MD, MSc , Kent D. Taylor PhD , Philip Greenland MD , Bruce M. Psaty MD, PhD , Russell P. Tracy PhD , Lin Yee Chen MD, MS , Amil M. Shah MD , Bing Yu PhD , Ravi B. Patel MD, MSc","doi":"10.1016/j.jacbts.2024.05.016","DOIUrl":null,"url":null,"abstract":"<div><div>A common missense variant in <em>ICAM1</em> among African American individuals (rs5491; pK56M) has been associated with risk of heart failure with preserved ejection fraction (HFpEF), but the pathways that lead to HFpEF among those with this variant are not clear. In this analysis of 92 circulating proteins and their associated networks, we identified 7 circulating inflammatory proteins associated with rs5491 among >600 African American individuals. Using weighted coexpression network analysis, 3 protein networks were identified, one of which was associated with rs5491. This protein network was most highly represented by members of the tumor necrosis receptor superfamily. The rs5491 variant demonstrated an inflammatory proteomic profile in a separate cohort of African American individuals. This analysis identifies inflammatory pathways that may drive HFpEF among African American individuals with the <em>ICAM1</em> pK56M (rs5491) variant.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 9","pages":"Pages 1073-1084"},"PeriodicalIF":8.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24002262/pdfft?md5=6a8e1da15f7d8bf280efb89154fd82d8&pid=1-s2.0-S2452302X24002262-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24002262","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
A common missense variant in ICAM1 among African American individuals (rs5491; pK56M) has been associated with risk of heart failure with preserved ejection fraction (HFpEF), but the pathways that lead to HFpEF among those with this variant are not clear. In this analysis of 92 circulating proteins and their associated networks, we identified 7 circulating inflammatory proteins associated with rs5491 among >600 African American individuals. Using weighted coexpression network analysis, 3 protein networks were identified, one of which was associated with rs5491. This protein network was most highly represented by members of the tumor necrosis receptor superfamily. The rs5491 variant demonstrated an inflammatory proteomic profile in a separate cohort of African American individuals. This analysis identifies inflammatory pathways that may drive HFpEF among African American individuals with the ICAM1 pK56M (rs5491) variant.
期刊介绍:
JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.